<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489201</url>
  </required_header>
  <id_info>
    <org_study_id>ZGDE1B</org_study_id>
    <nct_id>NCT02489201</nct_id>
  </id_info>
  <brief_title>A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer</brief_title>
  <official_title>A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, one-center, noncomparative, two-stages phase 1B trial assessed the tyrosine
      kinase inhibitor donafenib tosylate tablets(400 mg/d,200mg bid) in patients with advanced,
      inoperable oesophageal cancer progressing after chemotherapy .

      The primary endpoint is the safety.The secondary endpoints are tumor response and
      progression-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, noncomparative, two-part phase 1B trial recruited patients with advanced,
      inoperable oesophageal cancer. The primary objectives were to assess the safety for donafenib
      tosylate tablets .The secondary objectives were to estimate tumor response, progression-free
      survival, duration of response, and disease control rate (response plus stable disease); to
      evaluate changes in quality of life(QoL); This study is 2-stages designing. The investigators
      plan to enroll 19 patients in the first stage study. The investigators will start the
      secondary stage study if the disease control rate &gt;=8/19.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>54 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>donafenib tosilate tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donafenib tosilate tablets</intervention_name>
    <description>200mg,bid</description>
    <arm_group_label>donafenib tosilate tablets</arm_group_label>
    <other_name>CM4307</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients provided written, informed consent.

          -  Have histologically confirmed advanced oesophageal squamous-cell carcinoma, or type
             I/II Siewert junctional tumours.

          -  Have received up to two previous chemotherapy regimens( Platinum containing regimens &amp;
             Paclitaxel / docetaxel containing regimens).

          -  Have an Eastern Cooperative Oncology Group Performance status of 0-1.

          -  Have ability to swallow tablets.

          -  no contraindications to sorafenib or donafenib.

          -  Have either measurable or evaluable lesion on CT.

        Exclusion Criteria:

          -  Patients with brain metastases.

          -  Patients receiving cytotoxic chemotherapy, immunotherapy or hormonal therapy,
             radiotherapy to site of measurable or evaluable disease within the previous 4 weeks.

          -  Patients had evidence of clinically active interstitial lung disease or abnormal blood
             results by predefined criteria (serum bilirubin &gt;1.5 times upper limit of reference
             range, aspartate or alanine aminotransferase&gt;2.5 times the upper limit of normal if no
             demonstrable liver disease) .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianming Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Military Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rongrui Liu, Doctor</last_name>
    <phone>13911726595</phone>
    <email>liurongrui@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Cancer Center of Academy of Military Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Xu, Doctor</last_name>
      <phone>86-13910866712</phone>
      <email>jmxu2003@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Rongrui Liu</last_name>
      <phone>86-13911726595</phone>
      <email>liurongrui@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>donafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

